原文路透社:
https://reut.rs/3rsaHhk
藥商也是想把整個疫苗研發流程給縮短啦
特別是小藥商
各位鄉民怎麼看這篇？
大意:
1.目前開發出來的疫苗，經過大量公測後,
各藥商針對公測的數據後有個初步的結論
2.又由於原本疫苗臨床試驗的安慰劑組跟疫苗組，
開始認為這種臨床試驗是不道德的。
而且接種的人愈來愈多，抗体的樣本也愈來愈多，無法再做安慰劑組
再加上這次是合作的小藥商開發出來的疫苗，他們也沒有這麼多資金再研發下去
(Such randomized, controlled trials may no longer be considered ethical in
some countries,
as researchers cannot give a dummy shot to people where an
effective vaccine is widely available.
In addition, many of the new shots are being developed by small companies that may not be able to conduct very large
trials without government funding or a partner with deep pockets.
3.英國與歐萌正在制定免疫橋接的規則跟標準，美國則觀望中
European and UK health regulators are working with companies to set standards
for these so-called “immunobridging” studies.
The U.S. Food and Drug
Administration declined to say whether it would accept such trials for
next-generation vaccines.